Top Movers

AstraZeneca sells Atacand rights to Cheplapharm for $400m

By Frank Prenesti

Date: Friday 30 Oct 2020

(Sharecast News) - AstraZeneca said it was selling the commercial rights to its heart failure and hypertension drug Atacand and Atacand Plus in around 70 countries globally to Cheplapharm Arzneimittel for $400m.
The deal is expected to complete in the final quarter of 2020, AstraZeneca said on Friday, adding that $250m of the purchase price would be payable on completion and the rest in the first half of 2021.



Email this article to a friend

or share it with one of these popular networks:

Top of Page